Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Evaluating the link between Paraoxonase-1 levels and Alzheimer's disease development.

Cervellati C, Valacchi G, Tisato V, Zuliani G, Marsillach J.

Minerva Med. 2018 Oct 11. doi: 10.23736/S0026-4806.18.05875-5. [Epub ahead of print]

PMID:
30334443
2.

Ancient convergent losses of Paraoxonase 1 yield potential risks for modern marine mammals.

Meyer WK, Jamison J, Richter R, Woods SE, Partha R, Kowalczyk A, Kronk C, Chikina M, Bonde RK, Crocker DE, Gaspard J, Lanyon JM, Marsillach J, Furlong CE, Clark NL.

Science. 2018 Aug 10;361(6402):591-594. doi: 10.1126/science.aap7714.

PMID:
30093596
3.

Metals and Paraoxonases.

Costa LG, Cole TB, Garrick JM, Marsillach J, Furlong CE.

Adv Neurobiol. 2017;18:85-111. doi: 10.1007/978-3-319-60189-2_5. Review.

PMID:
28889264
4.

Paraoxonase-1 and Early-Life Environmental Exposures.

Marsillach J, Costa LG, Furlong CE.

Ann Glob Health. 2016 Jan-Feb;82(1):100-10. doi: 10.1016/j.aogh.2016.01.009. Review.

5.

Paraoxonases-1, -2 and -3: What are their functions?

Furlong CE, Marsillach J, Jarvik GP, Costa LG.

Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62. doi: 10.1016/j.cbi.2016.05.036. Epub 2016 May 26.

6.

Developmental expression of paraoxonase 2.

Garrick JM, Dao K, de Laat R, Elsworth J, Cole TB, Marsillach J, Furlong CE, Costa LG.

Chem Biol Interact. 2016 Nov 25;259(Pt B):168-174. doi: 10.1016/j.cbi.2016.04.001. Epub 2016 Apr 7.

7.

Announcing our finalists.

Burton C, Marsillach J, Zhang YS, Zhao W, Zheng X.

Bioanalysis. 2015;7(13):1667-73. doi: 10.4155/bio.15.90. Epub 2015 Jul 7.

8.

Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Marsillach J, Becker JO, Vaisar T, Hahn BH, Brunzell JD, Furlong CE, de Boer IH, McMahon MA, Hoofnagle AN; DCCT/EDIC Research Group.

J Proteome Res. 2015 May 1;14(5):2046-54. doi: 10.1021/pr5011586. Epub 2015 Mar 13.

9.

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase.

Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, MacCoss MJ, Hsieh EJ, Rettie AE, Furlong CE.

PLoS One. 2014 Oct 15;9(10):e110054. doi: 10.1371/journal.pone.0110054. eCollection 2014.

10.

Rare coding variation in paraoxonase-1 is associated with ischemic stroke in the NHLBI Exome Sequencing Project.

Kim DS, Crosslin DR, Auer PL, Suzuki SM, Marsillach J, Burt AA, Gordon AS, Meschia JF, Nalls MA, Worrall BB, Longstreth WT Jr, Gottesman RF, Furlong CE, Peters U, Rich SS, Nickerson DA, Jarvik GP; NHLBI Exome Sequencing Project.

J Lipid Res. 2014 Jun;55(6):1173-8. doi: 10.1194/jlr.P049247. Epub 2014 Apr 7.

11.

Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome.

Ferré N, Feliu A, García-Heredia A, Marsillach J, París N, Zaragoza-Jordana M, Mackness B, Mackness M, Escribano J, Closa-Monasterolo R, Joven J, Camps J.

Clin Biochem. 2013 Dec;46(18):1830-6. doi: 10.1016/j.clinbiochem.2013.08.020. Epub 2013 Sep 10.

PMID:
24028901
12.

Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Kim DS, Marsillach J, Furlong CE, Jarvik GP.

Pharmacogenomics. 2013 Sep;14(12):1495-515. doi: 10.2217/pgs.13.147. Review.

13.

Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease.

Soler N, García-Heredia A, Marsillach J, Mackness B, Mackness M, Joven J, Romero P, Camps J.

Invest Ophthalmol Vis Sci. 2013 Aug 28;54(8):5852-8. doi: 10.1167/iovs.13-11951.

PMID:
23900603
14.

Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: a nondirected metabolomic study.

García-Heredia A, Marsillach J, Rull A, Triguero I, Fort I, Mackness B, Mackness M, Shih DM, Joven J, Camps J.

Mediators Inflamm. 2013;2013:156053. doi: 10.1155/2013/156053. Epub 2013 May 22.

15.

Paraoxonase-1 status in patients with hereditary hemochromatosis.

Martinelli N, García-Heredia A, Roca H, Aranda N, Arija V, Mackness B, Mackness M, Busti F, Aragonès G, Pedro-Botet J, Pedica F, Cataldo I, Marsillach J, Joven J, Girelli D, Camps J.

J Lipid Res. 2013 May;54(5):1484-92. doi: 10.1194/jlr.P028977. Epub 2013 Mar 6.

16.

Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach.

García-Heredia A, Kensicki E, Mohney RP, Rull A, Triguero I, Marsillach J, Tormos C, Mackness B, Mackness M, Shih DM, Pedro-Botet J, Joven J, Sáez G, Camps J.

J Proteome Res. 2013 Apr 5;12(4):1946-55. doi: 10.1021/pr400050u. Epub 2013 Mar 8.

PMID:
23448543
17.

Protein adducts as biomarkers of exposure to organophosphorus compounds.

Marsillach J, Costa LG, Furlong CE.

Toxicology. 2013 May 10;307:46-54. doi: 10.1016/j.tox.2012.12.007. Epub 2012 Dec 20. Review.

18.

Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures.

Marsillach J, Hsieh EJ, Richter RJ, MacCoss MJ, Furlong CE.

Chem Biol Interact. 2013 Mar 25;203(1):85-90. doi: 10.1016/j.cbi.2012.10.019. Epub 2012 Nov 2.

19.

Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE.

Toxicology. 2013 May 10;307:115-22. doi: 10.1016/j.tox.2012.07.011. Epub 2012 Jul 31. Review.

20.

Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study.

Mackness B, Marsillach J, Elkeles RS, Godsland IF, Feher MD, Rubens MB, Flather MD, Humphries SE, Cooper J, Mackness M.

Dis Markers. 2012;33(2):101-12. doi: 10.3233/DMA-2012-0910.

21.

Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease.

Rull A, García R, Fernández-Sender L, García-Heredia A, Aragonès G, Beltrán-Debón R, Marsillach J, Alegret JM, Martín-Paredero V, Mackness B, Mackness M, Joven J, Camps J.

Atherosclerosis. 2012 Feb;220(2):545-51. doi: 10.1016/j.atherosclerosis.2011.11.021. Epub 2011 Nov 22.

PMID:
22153698
22.

Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.

Aragonès G, García-Heredia A, Guardiola M, Rull A, Beltrán-Debón R, Marsillach J, Alonso-Villaverde C, Mackness B, Mackness M, Pedro-Botet J, Pardo-Reche P, Joven J, Camps J.

J Lipid Res. 2012 Jan;53(1):168-74. doi: 10.1194/jlr.P018457. Epub 2011 Oct 14.

23.

Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease.

García-Heredia A, Marsillach J, Aragonès G, Guardiola M, Rull A, Beltrán-Debón R, Folch A, Mackness B, Mackness M, Pedro-Botet J, Joven J, Camps J.

Clin Biochem. 2011 Nov;44(16):1320-4. doi: 10.1016/j.clinbiochem.2011.08.003. Epub 2011 Aug 10.

PMID:
21854763
24.

Biomarkers of organophosphorus (OP) exposures in humans.

Marsillach J, Richter RJ, Kim JH, Stevens RC, MacCoss MJ, Tomazela D, Suzuki SM, Schopfer LM, Lockridge O, Furlong CE.

Neurotoxicology. 2011 Oct;32(5):656-60. doi: 10.1016/j.neuro.2011.06.005. Epub 2011 Jul 8.

25.

Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study.

Aragonès G, Guardiola M, Barreda M, Marsillach J, Beltrán-Debón R, Rull A, Mackness B, Mackness M, Joven J, Simó JM, Camps J.

J Lipid Res. 2011 May;52(5):1055-61. doi: 10.1194/jlr.D014134. Epub 2011 Feb 17.

26.

Paraoxonase-1 is only present in traceable amounts in seminal fluid and does not show any relationship with male subfertility.

Marsillach J, Lafuente R, Checa MA, Maestre-Martínez C, Fabián E, Brassesco M, Beltrán-Debón R, Aragonès G, Carreras R, Pedro-Botet J, Joven J, Camps J.

BJU Int. 2011 Aug;108(4):566-70. doi: 10.1111/j.1464-410X.2010.09888.x. Epub 2010 Nov 23.

27.

Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques.

Marsillach J, Camps J, Beltran-Debón R, Rull A, Aragones G, Maestre-Martínez C, Sabench F, Hernández M, Castillo DD, Joven J, Mackness M, Mackness B.

Eur J Clin Invest. 2011 Mar;41(3):308-14. doi: 10.1111/j.1365-2362.2010.02411.x. Epub 2010 Oct 21.

PMID:
20964682
28.

Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: the role of CCL2 genetic variants.

Alonso-Villaverde C, Aragonès G, Beltrán-Debón R, Fernández-Sender L, Rull A, Rodríguez-Sanabria F, Marsillach J, Pardo-Reche P, Camps J, Joven J.

Cytokine. 2010 Sep;51(3):251-8. doi: 10.1016/j.cyto.2010.05.008. Epub 2010 Jun 22.

PMID:
20573518
29.

Decreased serum arylesterase activity in autism spectrum disorders.

Gaita L, Manzi B, Sacco R, Lintas C, Altieri L, Lombardi F, Pawlowski TL, Redman M, Craig DW, Huentelman MJ, Ober-Reynolds S, Brautigam S, Melmed R, Smith CJ, Marsillach J, Camps J, Curatolo P, Persico AM.

Psychiatry Res. 2010 Dec 30;180(2-3):105-13. doi: 10.1016/j.psychres.2010.04.010. Epub 2010 May 21.

PMID:
20488557
30.

Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment.

Marsillach J, Aragonès G, Mackness B, Mackness M, Rull A, Beltrán-Debón R, Pedro-Botet J, Alonso-Villaverde C, Joven J, Camps J.

Lipids Health Dis. 2010 May 14;9:46. doi: 10.1186/1476-511X-9-46.

31.

Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results.

Camps J, Mackness M, Mackness B, Marsillach J, Joven J.

Clin Chem Lab Med. 2010 Jun;48(6):893-4. doi: 10.1515/CCLM.2010.156. No abstract available.

PMID:
20345229
32.

Human PON1, a biomarker of risk of disease and exposure.

Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP.

Chem Biol Interact. 2010 Sep 6;187(1-3):355-61. doi: 10.1016/j.cbi.2010.03.033. Epub 2010 Mar 23. Review.

33.

Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients.

Parra S, Marsillach J, Aragonès G, Rull A, Beltrán-Debón R, Alonso-Villaverde C, Joven J, Camps J.

Lipids Health Dis. 2010 Mar 25;9:32. doi: 10.1186/1476-511X-9-32.

34.

Interrelationships between paraoxonase-1 and monocyte chemoattractant protein-1 in the regulation of hepatic inflammation.

Camps J, Marsillach J, Rull A, Alonso-Villaverde C, Joven J.

Adv Exp Med Biol. 2010;660:5-18. doi: 10.1007/978-1-60761-350-3_2. Review.

PMID:
20221866
35.

Paraoxonase-1 in female infertility: a possible role against oxidative stress-induced inflammation.

Marsillach J, Checa MA, Pedro-Botet J, Carreras R, Joven J, Camps J.

Fertil Steril. 2010 Aug;94(3):1132-4. doi: 10.1016/j.fertnstert.2009.11.043. Epub 2010 Jan 25.

PMID:
20100610
36.

Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients.

Parra S, Marsillach J, Aragonés G, Beltrán R, Montero M, Coll B, Mackness B, Mackness M, Alonso-Villaverde C, Joven J, Camps J.

J Infect Dis. 2010 Feb 15;201(4):627-34. doi: 10.1086/650312.

PMID:
20078196
37.

Pitfalls in measuring high-density lipoprotein cholesterol concentrations in HIV-infected patients.

Aragonès G, Beltrán R, Rull A, Marsillach J, Rodríguez F, Alí SB, Fernández-Sender L, Camps J, Joven J, Alonso-Villaverde C.

HIV Med. 2010 Apr;11(4):260-5. doi: 10.1111/j.1468-1293.2009.00772.x. Epub 2009 Dec 3.

38.

Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation.

Parra S, Coll B, Aragonés G, Marsillach J, Beltrán R, Rull A, Joven J, Alonso-Villaverde C, Camps J.

HIV Med. 2010 Apr;11(4):225-31. doi: 10.1111/j.1468-1293.2009.00766.x. Epub 2009 Oct 21.

39.

Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs.

De Keyzer D, Karabina SA, Wei W, Geeraert B, Stengel D, Marsillach J, Camps J, Holvoet P, Ninio E.

Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2041-6. doi: 10.1161/ATVBAHA.109.196592. Epub 2009 Oct 1.

PMID:
19797705
40.

Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis.

Rull A, Rodríguez F, Aragonès G, Marsillach J, Beltrán R, Alonso-Villaverde C, Camps J, Joven J.

Cytokine. 2009 Dec;48(3):273-9. doi: 10.1016/j.cyto.2009.08.006. Epub 2009 Sep 12.

PMID:
19748796
41.

Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis.

Marsillach J, Oliveras-Ferraros C, Beltrán R, Rull A, Aragonès G, Alonso-Villaverde C, Vázquez-Martín A, Joven J, Menéndez JA, Camps J.

Clin Chem Lab Med. 2009;47(9):1097-9. doi: 10.1515/CCLM.2009.259.

PMID:
19728851
42.

Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity.

Camps J, Marsillach J, Joven J.

Mini Rev Med Chem. 2009 Jul;9(8):911-20. Review.

PMID:
19601886
43.

[Is there a relationship between cystatin C and inflammatory status, oxidative stress and other cardiovascular risk factors in non-diabetic patients with chronic kidney disease?].

Font R, Prats M, Gutiérrez C, Bardají A, Lalana M, Marsillach J, Camps J, Martínez Vea A.

Nefrologia. 2009;29(3):228-35. doi: 10.3265/Nefrologia.2009.29.3.5242.en.full. Spanish.

44.

Measurement of serum paraoxonase-1 activity in the evaluation of liver function.

Camps J, Marsillach J, Joven J.

World J Gastroenterol. 2009 Apr 28;15(16):1929-33.

45.

The paraoxonases: role in human diseases and methodological difficulties in measurement.

Camps J, Marsillach J, Joven J.

Crit Rev Clin Lab Sci. 2009;46(2):83-106. doi: 10.1080/10408360802610878. Review.

PMID:
19255916
46.

Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease.

Marsillach J, Camps J, Ferré N, Beltran R, Rull A, Mackness B, Mackness M, Joven J.

BMC Gastroenterol. 2009 Jan 14;9:3. doi: 10.1186/1471-230X-9-3.

47.

The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment.

Marsillach J, Aragonès G, Beltrán R, Caballeria J, Pedro-Botet J, Morcillo-Suárez C, Navarro A, Joven J, Camps J.

Clin Biochem. 2009 Jan;42(1-2):91-8. doi: 10.1016/j.clinbiochem.2008.09.120. Epub 2008 Oct 21.

PMID:
18977341
48.

Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues.

Marsillach J, Mackness B, Mackness M, Riu F, Beltrán R, Joven J, Camps J.

Free Radic Biol Med. 2008 Jul 15;45(2):146-57. doi: 10.1016/j.freeradbiomed.2008.03.023. Epub 2008 Apr 11.

PMID:
18440321
49.

Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis.

Franco-Pons N, Marsillach J, Joven J, Camps J, Closa D.

J Gastrointest Surg. 2008 May;12(5):891-9. doi: 10.1007/s11605-008-0502-2. Epub 2008 Mar 11.

PMID:
18330656
50.

Moderately high folic acid supplementation exacerbates experimentally induced liver fibrosis in rats.

Marsillach J, Ferré N, Camps J, Riu F, Rull A, Joven J.

Exp Biol Med (Maywood). 2008 Jan;233(1):38-47.

PMID:
18156304

Supplemental Content

Loading ...
Support Center